VANCOUVER, BC and MESA, AZ, July 10, 2013 /CNW/ - Avidus Management
Group Inc. ("Avidus" or the "Company") (TSX-V: AVD, OTC: ASNHF) and its
wholly owned subsidiary, Asantae, Inc. today announced the details of
its new functional beverage, IS2.
IS2 is a specialized, proprietary formula that uses high potency
extracts and bioavailable nutrients including Astralagus, Curcumin, and
Resveratrol to support the body's natural ability to protect, fight,
and rebuild against the effects of injury, illness, and disease.
The IS2 formula uses research done at many of the top nutraceutical and
nutritional institutes in North America to identify the specific
dosages and combinations needed to provide optimal benefits.
Dan Lundell, CEO said, "We are very excited about the launch of this
revolutionary beverage this fall. We are confident that this product
will provide significant health benefits and create excitement within
our network that will accelerate recruiting and revenue growth. Mr.
Ridley's experience and prior success within the functional beverage
category make this product launch an exciting strategic growth
opportunity as well as a natural extension of our mission to fight the
root causes of disease."
Doug Ridley, President, added, "Having built a company from the ground
up, and led a successful network of distributors that generated annual
sales of over $25 million, both focused on a functional beverage
product, I am thrilled about the pending launch of IS2. The functional
beverage space represents an enormous opportunity and we expect IS2 to
drive our intensive recruitment and growth initiatives."
Avidus Management Group Inc. (www.asantae.com) (TSX-V: AVD, OTC: ASNHF) through its wholly owned subsidiary, Asantae, Inc. develops, produces and markets innovative nutritional products
through direct and network marketing channels. The ingredients in
Avidus' products have been shown to reduce chronic low-grade
inflammation and oxidative stress, and support a healthy immune system
that, according to scientific and medical research, are the underlying
conditions for most modern epidemic diseases (diabetes, heart disease,
obesity, stroke, etc.).
This news release may contain forward-looking statements relating to the
Company's operations or to the environment in which it operates. Such
statements are based on operations, estimates, forecasts and
projections. They are not guarantees of future performance and involve
risks and uncertainties that are difficult to predict and may be beyond
the Company's control. A number of important factors could cause actual
outcomes and results to differ materially from those expressed in
forward-looking statements, including those set forth in the Company's
regulatory filings. In addition, such statements relate to the date on
which they are made and the Company disclaims any intention or
obligation to update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, save and
except as may be required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Avidus Management Group Inc.
For further information:
Avidus Management Group, Inc.
Dan Lundell, CEO/COO
10153 E Hampton Ave, Ste 101, Mesa, AZ, 85209 USA
P: 480-278-8712 / F: 480-383-6147
Sequoia Partners Inc.